Skip to main content
    V

    Vera Therapeutics Inc (VERA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.20
    -0.77 (-2.85%)

    Market Cap: $1.95B

    Last updated: Nov 17, 2026 at 4:30 PM ET

    Vera Therapeutics Inc (VERA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Vera Therapeutics (VERA) has a market cap of $1.95B and an enterprise value of $1.97B. It kept -4041.19% of revenue as net income over the last 12 months. Its share count is up 12.97% from a year earlier.

    Total Valuation

    Enterprise value is 1.03% above the market cap, as debt exceeds cash.

    Market Cap$1.95B
    Enterprise Value$1.97B
    Latest price (Nov 17, 2026)$26.20

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.40% in the quarter ended Sep 30, 2026 and grew 14.62% a year over 2 years.

    Shares Outstanding72.13M
    Shares Change (YoY)+12.97%
    Shares Change (QoQ)+0.40%
    Share Count Growth (2Y CAGR)+14.62%

    Valuation Ratios

    Sales and book value multiples are 183.9x and 5.7x.

    P/S Ratio183.9x
    Forward P/S62.5x
    P/B Ratio5.7x
    P/TBV Ratio6.0x

    Price Statistics

    The stock is down 7.58% over 52 weeks and trades 14.80% below its 50-day average.

    Beta (1Y)1.25
    52-Week Change-7.58%
    1-Month Change-9.41%
    3-Month Change-18.82%
    6-Month Change-21.20%
    5-Year Change+60.10%
    Total Return (1Y)-7.58%
    Total Return (3Y CAGR)+24.15%
    Total Return (5Y CAGR)-1.62%
    Return vs SPY (1Y)-20.93%
    Max Drawdown (1Y)-52.94%
    Max Drawdown (3Y)-62.09%
    Sharpe Ratio (1Y)-0.17
    Correlation with SPY (1Y)0.30
    50-Day Average$30.75
    200-Day Average$35.97
    52-Week Range$26.38 to $56.05
    RSI (14 Days)35.6
    Average Volume (20 Days)1.53M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.91x current liabilities, and total debt is 0.23x shareholder equity.

    Current Ratio7.91x
    Quick Ratio7.78x
    Debt / Equity0.23x
    Interest Coverage-57.65x

    Returns and Efficiency

    Return on invested capital is -83.02% over the last 12 months, against a 5-year average of -46.60%.

    Return on Equity (ROE)-124.65%
    Return on Assets (ROA)-89.17%
    Return on Invested Capital (ROIC)-83.02%
    ROE (5Y Average)-66.60%
    ROA (5Y Average)-45.07%
    ROIC (5Y Average)-46.60%
    Asset Turnover0.02x
    Inventory Turnover0.93x
    Receivables Turnover1.72x
    Cash Conversion Cycle-1319 days

    Scores

    VERA has an Altman Z-Score of 3.26, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score3.26
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $10.28M over the last 12 months.

    Revenue$10.28M
    Gross Profit$8.11M
    Operating Income-$427.53M
    Pretax Income-$415.31M
    Net Income-$415.31M
    Reported EPS (TTM)-$5.90

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 71.54% of the $465.75M in total assets.

    Cash and Equivalents$55.32M
    Total Debt$75.43M
    Net Debt$20.11M
    Net Debt Per Share$0.28
    Working Capital$385.51M
    Shareholder Equity$333.19M
    Book Value Per Share$4.62
    Tangible Book Value$312.69M
    Tangible Book Per Share$4.34
    Total Assets$465.75M
    Total Liabilities$132.57M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$375.92M
    FCF Per Share-$5.22
    Depreciation and Amortization$2.76M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -4160.07%.

    Gross Margin78.89%
    Operating Margin-4160.07%
    Pretax Margin-4041.18%
    Net Margin-4041.19%

    Growth

    Book Value Per Share Growth (2Y CAGR)+102.88%
    Tangible Book Per Share Growth (2Y CAGR)+102.88%

    Revenue and profit by year

    Dividends and Yields

    VERA does not pay a dividend.

    Buyback Yield-16.60%
    Shareholder Yield-16.60%

    Peer Position

    Against 7 similar companies, VERA has the highest P/S.

    P/S Ratio183.9x vs 7.4x median
    ROIC-83.02% vs -29.73% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About VERA

    What is VERA's market cap?

    Vera Therapeutics has a market cap of $1.95B. Its enterprise value, which adds debt and subtracts cash, is $1.97B.

    How many shares of VERA are outstanding?

    Vera Therapeutics has 72.13M shares outstanding. The count is up 12.97% from a year earlier.

    Does VERA pay a dividend?

    No. Vera Therapeutics does not pay a dividend.

    How much debt does VERA have?

    Vera Therapeutics has $75.43M of total debt and $55.32M of cash and equivalents, a net debt position of $20.11M.